Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    24-November-2000      
Issue 225 Next Update - 14:00 UTC 08:00 EST    25-November-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Zomig® An Effective Migraine Treatment Strategy

Information From This Week's Journal Of The American Medical Association (JAMA)

A study published in the November 22 issue of the Journal of the American Medical Association (JAMA) suggests that stratified care which included Zomig® (zolmitripan) Tablets is a more effective migraine treatment strategy than step care approaches.(1)

The Disability in Strategies of Care (DISC) study, which compared the clinical benefits of stratified care with two variants of step care, demonstrated that patients achieve greater headache response and have less disability time when using a stratified care approach.(1)

"This study is great news for migraine patients, many of whom may suffer through a lengthy and painful process of identifying the appropriate medicine needed to effectively treat their illness," said study lead author Richard B. Lipton, MD, of the Albert Einstein College of Medicine in Bronx, NY and Innovative Medical Research. "By determining the severity of a patient's illness using the Migraine Disability Assessment tool (MIDAS), the treatment process becomes more efficient. Stratifying care according to disability allows patients to be more confident that their pain will be more efficiently treated."

A stratified care approach to treatment matches treatment to illness severity or other factors. In the DISC study, initial stratified care treatment of migraine attacks was based on the degree of headache-related disability, as measured by the MIDAS questionnaire.(1) The MIDAS questionnaire measures the severity of disability according to lost time in different activities.(2) Patients having a lower level of disability, as measured by MIDAS, were treated with aspirin plus metoclopramide; patients with more serious disability were treated with Zomig.

Step care is a trial and error approach in which treatment is escalated after non-specific medications fail.(1) In the DISC study, patients were asked to treat six migraine attacks using either a step care within or step care across attacks approach. Initial treatment for step care within attacks was a combination of aspirin and metoclopramide. If headache relief was not achieved within two hours, treatment was escalated to Zomig® (zolmitripan), a widely used oral triptan.(1) Initial treatment for step care across attacks was the combination of aspirin plus metoclopramide for the first three migraine attacks. If analgesic treatment was inadequate, patients received Zomig for the next three attacks.

This international, open-label, randomized, three-arm, controlled, multiple attack study involved 88 clinical centers in 13 countries.(1) During the course of the 15-month clinical trial (December 1997 to March 1999), 835 patients treated 4,945 migraine attacks.(1) Eligible patients ranged in age from 18 to 65 years, and had onset of their first migraine before age 50.(1) Patients recorded details of their migraine attacks and pain intensity (0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain) two hours after an initial dose of study medication; functional status (0=inability to do any activity, 100=normal function) was recorded four hours after the initial dose.(1) Based on their MIDAS scores, patients following stratified care guidelines received either the migraine-specific therapy Zomig or aspirin plus metoclopramide for six migraine attacks. Initial treatment for patients following the step care approaches was aspirin plus metoclopramide, irrespective of their MIDAS score. Treatment was escalated to Zomig for patients who had inadequate headache response.

"I believe this is the first randomized trial to compare strategies of selecting and sequencing migraine medications," said study co-author Walter F. Stewart, PhD, of Innovative Medical Research and Johns Hopkins University. "The results show that if doctors consider headache-related disability as measured by MIDAS in selecting migraine therapies, patient outcomes improve. The DISC study suggests that patients achieve faster headache response and experience less disability time when treated using a stratified care approach."

Headache response at two hours was significantly greater across six attacks when using stratified care versus both step care approaches.(1) Similar results were evident for headache response at one hour. Further, disability time averaged across six attacks was significantly lower for stratified care compared with both step care approaches.(1) Adverse events for all treatment arms were predominantly mild to moderate and are consistent with other 5-HT1B/1D agonists. Most common were weakness, nausea, dizziness, tingling and drowsiness.

Zomig® (zolmitriptan) conventional tablets are indicated for the acute treatment of migraine with or without aura in adults. Zomig is not intended to prevent migraine. Zomig is intended to relieve migraine pain at any time during a migraine attack. Zomig is contraindicated for patients with uncontrolled hypertension, ischemic heart disease, or other significant underlying heart disease. In addition, Zomig should not be administered to patients who are hypersensitive to zolmitriptan or any of the inactive ingredients of Zomig Tablets. Zomig should not be taken by patients who have certain types of heart disease or uncontrolled high blood pressure. Very rarely, some people without recognized heart disease may have serious heart-related problems. Also, if patients think they may have risk factors for heart disease such as smoking, high blood pressure, high cholesterol, or a family history of heart disease, or if they are pregnant, nursing, or taking medications, patients should talk to their healthcare provider. The most common side effects associated with taking Zomig include dizziness; tightness, pressure or pain in the neck, throat, or jaw; fatigue; tingling sensations; drowsiness; or nausea.

  • (1) Lipton RB, Stewart W, Stone A, et al. Stratified Care is More Effective than Step Care Strategies for Migraine: Results of the Disability in Strategies of Care (DISC) Study. Journal of the American Medical Association. November 22, 2000.
  • (2) Migraine Disability Assessment Questionnaire. Innovative Medical Research 1999.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.